Erratum: Simvastatin attenuates oxidative stress, NF-κB activation, and artery calcification in LDLR-/- Mice fed with high fat diet via down-regulation of tumor necrosis Factor-α and TNF receptor 1 (PLoS ONE (2015) 10:12 (e0143686) 10.1371/journal.pone.0143686);Simvastatin attenuates oxidative stress, NF-κB activation, and artery calcification in LDLR-/-mice fed with high fat diet via down-regulation of tumor necrosis factor-α and TNF receptor 1

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Lin, Chih Pei ^a,b   Huang, Po Hsun ^a,c   Lai, Chung Fang ^d   Chen, Jaw Wen ^a,c   Lin, Shing Jong ^a,c   Chen, Jia Shiong ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Dept of Biotechnology and Laboratory Science in Medicine and Institute of Biotechnology in Medicine ^*  (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACETYLCYSTEINE; ALKALINE PHOSPHATASE; APOCYNIN; BONE MORPHOGENETIC PROTEIN 2; CHOLESTEROL; GLUCOSE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NADPH OXIDASE SUBUNIT P47; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RUNX2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN RECEPTOR; TUMOR NECROSIS FACTOR;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTIC SMOOTH MUSCLE CALCIFICATION; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; SOFT TISSUE CALCIFICATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; CALCINOSIS; DRUG EFFECTS; GENE INACTIVATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; ARTERIOSCLEROSIS; CALCINOSIS; DIET, HIGH-FAT; DOWN-REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; OXIDATIVE STRESS; RECEPTORS, LDL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961289252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148590     Document Type: Erratum

References (64)

1. Belovici MI, Pandele GI. [Arterial media calcification in patients with type 2 diabetes mellitus]. Rev Med Chir Soc Med Nat Iasi. 2008; 112:21-34.
2. Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation. 2001; 104:2679-84.
3. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008; 19:213-6.
4. Zhu D, Mackenzie NC, Farquharson C, Macrae VE, Mechanisms and clinical consequences of vascular calcification. Front Endocrinol (Lausanne). 2012; 3:95.
5. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008; 283:15319-27. doi: 10.1074/jbc.M800021200
6. Tang FT, Chen SR, Wu XQ, Wang TQ, Chen JW, Li J, et al. Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int. 2006; 79:326-39.
7. Jensky NE, Criqui MH, Wright MC, Wassel CL, Brody SA, Allison MA, et al. Blood pressure and vascular calcification. Hypertension. 2010; 55:990-7. doi: 10.1161/HYPERTENSIONAHA.109.147520
8. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008; 52:843-50. E doi: 10.1016/j.jacc.2008.05.043
9. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008; 31:S170-80. doi: 10.2337/dc08-s247
10. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006; 260:192-210.
11. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circulation research. 2005; 97:105-14.
12. Sun Y, Byon C, Yuan K, Chen J, Mao X, Heath JM, et al. Smooth Muscle Cell-Specific Runx2 Deficiency InhibitsVascular Calcification. Circulation research. 2012, 111:543-52 doi: 10.1161/CIRCRESAHA.112.267237
13. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000; 24:391-5.
14. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005; 115:1210-20.
15. Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA. Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem. 2008; 283:20505-22. doi: 10.1074/jbc.M800851200
16. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-Alpha-dependent signals in diabetic Ldlr-/-mice. Arteriosclerosis, thrombosis, and vascular biology. 2007; 27:2589-96.
17. Al-Aly Z. Medial vascular calcification in diabetes mellitus and chronic kidney disease: The role of inflammation. Cardiovasc Hematol Disord Drug Targets. 2007; 7:1-6.
18. Lai CF, Shao JS, Behrmann A, Krchma K, Cheng SL, Towler DA, et al. TNFR1-Activated reactive oxidative species signals up-regulate osteogenic Msx2 programs in aortic myofibroblasts. Endocrinology. 2012; 153:3897-910. doi: 10.1210/en.2012-1216
19. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circulation research. 2006; 99:1044-59.
20. Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. 2008; 23:1798-805. doi: 10.1359/jbmr.080604
21. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circulation research. 2000; 87:1055-62.
22. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109:III39-43.
23. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circulation research. 2006; 98:1024-31.
24. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359:1125-6.
25. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007; 49:554-61.
26. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352:2389-97.
27. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Forster A, Friedrich G, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: A multicenter, randomized, double-blind trial. Circulation. 2006; 113:427-37.
28. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: A systematic review. Current vascular pharmacology. 2010; 8:638-44.
29. Ballard KD, Lorson L, White CM, Thompson PD, Taylor BA. Effect of Simvastatin on Arterial Stiffness in Patients with Statin Myalgia. Advances in preventive medicine. 2015; 2015:351059. doi: 10.1155/2015/351059
30. Ribichini F, Pugno F, Ferrero V, Bussolati G, Feola M, Russo P, et al. Cellular immunostaining of angiotensin-converting enzyme in human coronary atherosclerotic plaques. J Am Coll Cardiol. 2006; 47:1143-9.
31. Lin FY, Chen YH, Tasi JS, Chen JW, Yang TL, Wang HJ, et al. Endotoxin induces toll-like receptor 4 expression in vascular smooth muscle cells via NADPH oxidase activation and mitogen-Activated protein kinase signaling pathways. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26:2630-7.
32. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney international. 2004; 66:2293-9.
33. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney international. 2002; 62:1724-31.
34. Frey RS, Rahman A, Kefer JC, Minshall RD, Malik AB. PKCzeta regulates TNF-Alpha-induced activation of NADPH oxidase in endothelial cells. Circulation research. 2002; 90:1012-9.
35. Smith KR, Klei LR, Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. American journal of physiology. 2001; 280:L442-9.
36. Vinten-Johansen J. Physiological effects of peroxynitrite: potential products of the environment. Circulation research. 2000; 87:170-2.
37. Koppula S, Kumar H, Kim IS, Choi DK. Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease. Mediators Inflamm. 2012:823902. doi: 10.1155/2012/823902
38. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2005; 65:16-27.
39. Lee HL, Woo KM, Ryoo HM, Baek JH, Tumor necrosis factor-Alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun. 2010, 391:1087-92. doi: 10.1016/j.bbrc.2009.12.027
40. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, et al. Simvastatin antagonizes tumor necrosis factor-Alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-Activated protein kinase pathway. J Endocrinol.2008; 196:601-13. doi: 10.1677/JOE-07-0532
41. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr., Pomerantzeff PM, et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arteriosclerosis, thrombosis, and vascular biology. 2008; 28:463-70.
42. Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007; 1117:40-50.
43. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol. 2006; 168:629-38.
44. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-Alpha, H2O2, and high intravascular pressure. Circulation. 2005; 111:2364-72.
45. Hadad N, Tuval L, Elgazar-Carmom V, Levy R, Endothelial ICAM-1 protein induction is regulated by cytosolic phospholipase A2alpha via both NF-kappaB and CREB transcription factors. J Immunol. 2011, 186:1816-27. doi: 10.4049/jimmunol.1000193
46. Zhu NL, Li C, Huang HH, Sebald M, Londhe VA, Heisterkamp N, et al. TNF-Alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells. Gene. 2007; 393:70-80.
47. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone. 2009; 45:367-76 doi: 10.1016/j.bone.2009.04.252
48. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001; 292:1160-4.
49. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arteriosclerosis, thrombosis, and vascular biology. 2002; 22:1452-8.
50. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arteriosclerosis, thrombosis, and vascular biology. 1996; 16:978-83.
51. Soor GS, Vukin I, Leong SW, Oreopoulos G, Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology. 2008; 40:385-91. doi: 10.1080/00313020802036764
52. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001; 11:372-7.
53. Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002; 105:650-5.
54. Yamada S, Taniguchi M, Tokumoto M, Toyonaga J, Fujisaki K, Suehiro T, et al. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res. 2012; 27:474-85. doi: 10.1002/jbmr.539
55. Kim H, Kim HJ, Lee K, Kim JM, Kim HS, Kim JR, et al. alpha-Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway. J Cell Mol Med. 2012; 16:273-86. doi: 10.1111/j.1582-4934.2011.01294.x
56. Trion A, van der Laarse A. Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J. 2004; 147:808-14.
57. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arteriosclerosis, thrombosis, and vascular biology. 2002; 22:1832-7.
58. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998; 31:684-91.
59. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110:1291-5
60. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57:1535-45. doi: 10.1016/j.jacc.2010.10.047
61. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008; 117:2938-48. doi: 10.1161/CIRCULATIONAHA.107.743161
62. Ferreira TS, Lanzetti M, Barroso MV, Rueff-Barroso CR, Benjamim CF, de Brito-Gitirana L, et al. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation. 2014; 37:1355-65. doi: 10. 1007/s10753-014-9860-y
63. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000; 32:164-76.
64. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999; 353:983-4.